{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Piotrowski AF"],"funding":["NCI NIH HHS","BeOne Medicines Ltd.","NIH HHS"],"pagination":["541"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12562933"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(10)"],"pubmed_abstract":["Pamiparib, a small-molecule poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor, demonstrates strong PARP-DNA complex trapping, antitumor activity, and blood-brain barrier penetration. This phase Ib/II dose-escalation study (NCT03150862) investigated pamiparib's tolerability/safety and efficacy when combined with radiotherapy and/or low-dose temozolomide (TMZ) in patients with treatment-naïve (Arms A and B) and recurrent/refractory (Arm C) glioblastoma. The recommended phase II dose for Arm A was pamiparib 60 mg twice daily (BID) for 6 weeks with 6-7 weeks radiotherapy; the recommended dose for Arm C was pamiparib 60 mg BID plus 60 mg TMZ (days 1-7; 28-day cycle). The Arm B escalation cohort completed enrollment; the expansion cohort was not opened. Grade ≥3 treatment-emergent adverse events"],"journal":["Current oncology (Toronto, Ont.)"],"pubmed_title":["Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naive or Recurrent/Refractory Glioblastoma."],"pmcid":["PMC12562933"],"funding_grant_id":["0","1P30CA008748-24","P30 CA008748"],"pubmed_authors":["Gisin V","Piotrowski AF","Shih K","Badruddoja M","Cloughesy T","Zhu Z","Giglio P","Colman H","Campian JL","Wen PY","Butowski N"],"additional_accession":[]},"is_claimable":false,"name":"Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naive or Recurrent/Refractory Glioblastoma.","description":"Pamiparib, a small-molecule poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor, demonstrates strong PARP-DNA complex trapping, antitumor activity, and blood-brain barrier penetration. This phase Ib/II dose-escalation study (NCT03150862) investigated pamiparib's tolerability/safety and efficacy when combined with radiotherapy and/or low-dose temozolomide (TMZ) in patients with treatment-naïve (Arms A and B) and recurrent/refractory (Arm C) glioblastoma. The recommended phase II dose for Arm A was pamiparib 60 mg twice daily (BID) for 6 weeks with 6-7 weeks radiotherapy; the recommended dose for Arm C was pamiparib 60 mg BID plus 60 mg TMZ (days 1-7; 28-day cycle). The Arm B escalation cohort completed enrollment; the expansion cohort was not opened. Grade ≥3 treatment-emergent adverse events","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-05-15T03:18:27.181Z","creation":"2026-05-15T03:12:26.29Z"},"accession":"S-EPMC12562933","cross_references":{"pubmed":["41149461"],"doi":["10.3390/curroncol32100541"]}}